209 related articles for article (PubMed ID: 22743595)
1. Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies.
Wandeler G; Keiser O; Mulenga L; Hoffmann CJ; Wood R; Chaweza T; Brennan A; Prozesky H; Garone D; Giddy J; Chimbetete C; Boulle A; Egger M;
J Acquir Immune Defic Syndr; 2012 Sep; 61(1):41-8. PubMed ID: 22743595
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa.
Wandeler G; Gerber F; Rohr J; Chi BH; Orrell C; Chimbetete C; Prozesky H; Boulle A; Hoffmann CJ; Gsponer T; Fox MP; Zwahlen M; Egger M;
Antivir Ther; 2014; 19(5):521-5. PubMed ID: 24296645
[TBL] [Abstract][Full Text] [Related]
3. Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.
Mulenga L; Musonda P; Mwango A; Vinikoor MJ; Davies MA; Mweemba A; Calmy A; Stringer JS; Keiser O; Chi BH; Wandeler G;
Clin Infect Dis; 2014 May; 58(10):1473-80. PubMed ID: 24585558
[TBL] [Abstract][Full Text] [Related]
4. Brief Report: Assessing the Association Between Changing NRTIs When Initiating Second-Line ART and Treatment Outcomes.
Rohr JK; Ive P; Horsburgh CR; Berhanu R; Hoffmann CJ; Wood R; Boulle A; Giddy J; Prozesky H; Vinikoor M; Mwanza MW; Wandeler G; Davies MA; Fox MP
J Acquir Immune Defic Syndr; 2018 Apr; 77(4):413-416. PubMed ID: 29206723
[TBL] [Abstract][Full Text] [Related]
5. Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia.
Chi BH; Mwango A; Giganti M; Mulenga LB; Tambatamba-Chapula B; Reid SE; Bolton-Moore C; Chintu N; Mulenga PL; Stringer EM; Sheneberger R; Mwaba P; Stringer JS
J Acquir Immune Defic Syndr; 2010 May; 54(1):63-70. PubMed ID: 20009765
[TBL] [Abstract][Full Text] [Related]
6. Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir.
Njuguna C; Orrell C; Kaplan R; Bekker LG; Wood R; Lawn SD
PLoS One; 2013; 8(5):e63596. PubMed ID: 23717451
[TBL] [Abstract][Full Text] [Related]
7. Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.
Velen K; Lewis JJ; Charalambous S; Grant AD; Churchyard GJ; Hoffmann CJ
PLoS One; 2013; 8(5):e64459. PubMed ID: 23691224
[TBL] [Abstract][Full Text] [Related]
8. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
Labhardt ND; Bader J; Lejone TI; Ringera I; Puga D; Glass TR; Klimkait T
Trop Med Int Health; 2015 Jul; 20(7):914-8. PubMed ID: 25782332
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
Di Giambenedetto S; Torti C; Prosperi M; Manca N; Lapadula G; Paraninfo G; Ladisa N; Zazzi M; Trezzi M; Cicconi P; Corsi P; Nasta P; Cauda R; De Luca A; ; ;
Infection; 2009 Oct; 37(5):438-44. PubMed ID: 19669091
[TBL] [Abstract][Full Text] [Related]
10. Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir.
Brennan AT; Shearer K; Maskew M; Long L; Sanne I; Fox MP
Trop Med Int Health; 2014 May; 19(5):490-8. PubMed ID: 24589363
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa.
Skhosana L; Steegen K; Bronze M; Lukhwareni A; Letsoalo E; Papathanasopoulos MA; Carmona SC; Stevens WS
PLoS One; 2015; 10(2):e0118145. PubMed ID: 25659108
[TBL] [Abstract][Full Text] [Related]
12. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
; Mugyenyi P; Walker AS; Hakim J; Munderi P; Gibb DM; Kityo C; Reid A; Grosskurth H; Darbyshire JH; Ssali F; Bray D; Katabira E; Babiker AG; Gilks CF; Grosskurth H; Munderi P; Kabuye G; Nsibambi D; Kasirye R; Zalwango E; Nakazibwe M; Kikaire B; Nassuna G; Massa R; Fadhiru K; Namyalo M; Zalwango A; Generous L; Khauka P; Rutikarayo N; Nakahima W; Mugisha A; Todd J; Levin J; Muyingo S; Ruberantwari A; Kaleebu P; Yirrell D; Ndembi N; Lyagoba F; Hughes P; Aber M; Lara AM; Foster S; Amurwon J; Wakholi BN; Whitworth J; Wangati K; Amuron B; Kajungu D; Nakiyingi J; Omony W; Fadhiru K; Nsibambi D; Khauka P; Mugyenyi P; Kityo C; Ssali F; Tumukunde D; Otim T; Kabanda J; Musana H; Akao J; Kyomugisha H; Byamukama A; Sabiiti J; Komugyena J; Wavamunno P; Mukiibi S; Drasiku A; Byaruhanga R; Labeja O; Katundu P; Tugume S; Awio P; Namazzi A; Bakeinyaga GT; Katabira H; Abaine D; Tukamushaba J; Anywar W; Ojiambo W; Angweng E; Murungi S; Haguma W; Atwiine S; Kigozi J; Namale L; Mukose A; Mulindwa G; Atwiine D; Muhwezi A; Nimwesiga E; Barungi G; Takubwa J; Murungi S; Mwebesa D; Kagina G; Mulindwa M; Ahimbisibwe F; Mwesigwa P; Akuma S; Zawedde C; Nyiraguhirwa D; Tumusiime C; Bagaya L; Namara W; Kigozi J; Karungi J; Kankunda R; Enzama R; Latif A; Hakim J; Robertson V; Reid A; Chidziva E; Bulaya-Tembo R; Musoro G; Taziwa F; Chimbetete C; Chakonza L; Mawora A; Muvirimi C; Tinago G; Svovanapasis P; Simango M; Chirema O; Machingura J; Mutsai S; Phiri M; Bafana T; Chirara M; Muchabaiwa L; Muzambi M; Mutowo J; Chivhunga T; Chigwedere E; Pascoe M; Warambwa C; Zengeza E; Mapinge F; Makota S; Jamu A; Ngorima N; Chirairo H; Chitsungo S; Chimanzi J; Maweni C; Warara R; Matongo M; Mudzingwa S; Jangano M; Moyo K; Vere L; Mdege N; Machingura I; Katabira E; Ronald A; Kambungu A; Lutwama F; Mambule I; Nanfuka A; Walusimbi J; Nabankema E; Nalumenya R; Namuli T; Kulume R; Namata I; Nyachwo L; Florence A; Kusiima A; Lubwama E; Nairuba R; Oketta F; Buluma E; Waita R; Ojiambo H; Sadik F; Wanyama J; Nabongo P; Oyugi J; Sematala F; Muganzi A; Twijukye C; Byakwaga H; Ochai R; Muhweezi D; Coutinho A; Etukoit B; Gilks C; Boocock K; Puddephatt C; Grundy C; Bohannon J; Winogron D; Gibb DM; Burke A; Bray D; Babiker A; Walker AS; Wilkes H; Rauchenberger M; Sheehan S; Spencer-Drake C; Taylor K; Spyer M; Ferrier A; Naidoo B; Dunn D; Goodall R; Darbyshire JH; Peto L; Nanfuka R; Mufuka-Kapuya C; Kaleebu P; Pillay D; Robertson V; Yirrell D; Tugume S; Chirara M; Katundu P; Ndembi N; Lyagoba F; Dunn D; Goodall R; McCormick A; Lara AM; Foster S; Amurwon J; Wakholi BN; Kigozi J; Muchabaiwa L; Muzambi M; Weller I; Babiker A; Bahendeka S; Bassett M; Wapakhabulo AC; Darbyshire JH; Gazzard B; Gilks C; Grosskurth H; Hakim J; Latif A; Mapuchere C; Mugurungi O; Mugyenyi P; Burke C; Jones S; Newland C; Pearce G; Rahim S; Rooney J; Smith M; Snowden W; Steens JM; Breckenridge A; McLaren A; Hill C; Matenga J; Pozniak A; Serwadda D; Peto T; Palfreeman A; Borok M; Katabira E
Lancet; 2010 Jan; 375(9709):123-31. PubMed ID: 20004464
[TBL] [Abstract][Full Text] [Related]
13. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen.
Sunpath H; Wu B; Gordon M; Hampton J; Johnson B; Moosa MY; Ordonez C; Kuritzkes DR; Marconi VC
AIDS; 2012 Aug; 26(13):1679-84. PubMed ID: 22739389
[TBL] [Abstract][Full Text] [Related]
14. Comparative outcomes of tenofovir-based and zidovudine-based antiretroviral therapy regimens in Lusaka, Zambia.
Chi BH; Mwango A; Giganti MJ; Sikazwe I; Moyo C; Schuttner L; Mulenga LB; Bolton-Moore C; Chintu NT; Sheneberger R; Stringer EM; Stringer JS
J Acquir Immune Defic Syndr; 2011 Dec; 58(5):475-81. PubMed ID: 21857354
[TBL] [Abstract][Full Text] [Related]
15. Zidovudine impairs immunological recovery on first-line antiretroviral therapy: collaborative analysis of cohort studies in southern Africa.
Wandeler G; Gsponer T; Mulenga L; Garone D; Wood R; Maskew M; Prozesky H; Hoffmann C; Ehmer J; Dickinson D; Davies MA; Egger M; Keiser O;
AIDS; 2013 Sep; 27(14):2225-32. PubMed ID: 23660577
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.
von Wyl V; Cambiano V; Jordan MR; Bertagnolio S; Miners A; Pillay D; Lundgren J; Phillips AN
PLoS One; 2012; 7(8):e42834. PubMed ID: 22905175
[TBL] [Abstract][Full Text] [Related]
17. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa.
Keiser O; Chi BH; Gsponer T; Boulle A; Orrell C; Phiri S; Maxwell N; Maskew M; Prozesky H; Fox MP; Westfall A; Egger M;
AIDS; 2011 Sep; 25(14):1761-9. PubMed ID: 21681057
[TBL] [Abstract][Full Text] [Related]
19. [Immunological effectiveness of the nucleoside/nucleotide analog combinations, tenofovir + lamivudine, didanosine + lamivudine and tenofovir + didanosine, in patients with HIV infection and sustained viral suppression].
Cervero M; Torres R; Jusdado JJ; Rodríguez-Rosado R; Del Alamo M; García-Benaya E
Enferm Infecc Microbiol Clin; 2006; 24(7):426-30. PubMed ID: 16956530
[TBL] [Abstract][Full Text] [Related]
20. Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study.
Blanco JR; Caro-Murillo AM; Castaño MA; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Riera M; Pulido F; Vera F; Romero-Palacios A; Aguirrebengoa K; Portilla J; Ferrer P; Pedrol E
HIV Clin Trials; 2013; 14(5):204-15. PubMed ID: 24144897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
